埃拉菲布拉诺:首次获得批准
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Drugs
|August 7, 2024
概括
作为PPAR激动剂的Elafibranor已经获得了美国对原发性胆道胆炎 (PBC) 的加速批准. 这一里程碑为PBC患者提供了新的治疗选择,这些患者对ursodeoxycholic acid的反应或不耐受性不足.
科学领域:
- 药理学和胃肠病学 药理学和胃肠病学
- 药物发展和监管事务
背景情况:
- 初级胆道胆炎 (PBC) 是一种慢性肝病,需要新的治疗策略.
- 对于一些患者来说,现有的治疗方法,如ursodeoxycholic acid (UDCA),存在局限性.
- 过氧体增殖器激活受体 (PPAR) 激动剂代表了肝脏疾病的有前途的一类.
研究的目的:
- 要总结elafibranor用于PBC治疗的发展里程碑.
- 为了突出导致elafibranor批准的监管途径.
主要方法:
- 审查elafibranor的发展史和临床试验数据.
- 分析美国和欧盟的监管提交和批准.
- 专注于elafibranor作为PPAR激动剂的机制.
主要成果:
- 2024年6月10日,Elafibranor在美国获得了PBC的加速批准.
- 批准是基于性酸酶 (ALP) 降低在患者不充分的UDCA反应或不耐受性.
- 此外,Elafibranor在欧盟也获得了积极的评价.
结论:
- 伊拉非布拉诺代表了PBC治疗的重大进展.
- 这种一流的PPAR激动剂为特定的PBC患者群体提供了新的治疗选择.
- 批准标志着该药物从开发到患者获取的旅程中的一个关键里程碑.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
406
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
147
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
147
Drugs for Treatment of Diarrhea-Predominant IBS
156
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
156
Antihypertensive Drugs: Direct Renin Inhibitors
517
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
517
Cardiovascular Drugs: Classification based on Therapeutic Indications
2.1K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.1K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
720
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
720


